Please be aware that the information provided is a summary of select releases made to the ASX, as evaluated and interpreted by ASX Briefs. It is important to thoroughly read the entire original release before forming an opinion, rather than relying solely on the brief overview presented here. ASX Briefs is not associated with the ASX. ASX Briefs is an experimental AI project incorporating chatGPT, and as such, does not guarantee the accuracy of the information provided.
Biotron Limited has commenced a Phase 2 clinical trial with its lead antiviral drug BIT225 for the treatment of COVID-19.
The trial aims to determine if 7 days of treatment with BIT225 results in a reduction in SARS-CoV-2 blood viral load, favorable changes in viral and immune markers, and improvement in clinical symptoms.
BIT225 has shown good activity against SARS-CoV-2 and prevented disease development in a COVID-19 mouse model, demonstrating antiviral, immune modulatory, and clinical benefits.